Trimeris Shareholder Tries To Halt $81M Arigene Deal
Aiming to put the brakes on Arigene Co. Ltd.'s acquisition of biopharmaceutical company Trimeris Inc., a Trimeris shareholder has launched a putative class action alleging that the company and its board...To view the full article, register now.
Already a subscriber? Click here to view full article